Get the latest weekly fluid news direct to your inbox.

Sign up for our free newsletter now.
logo
menu

Emerson acquires MYNAH Technologies

MYNAH’s simulation models, including a bioreactor model for biotech organisations, help facilities to improve production and reduce risk.
MYNAH’s simulation models, including a bioreactor model for biotech organisations, help facilities to improve production and reduce risk.

Emerson has completed the acquisition of MYNAH Technologies, a provider of dynamic simulation and operator training software. Prior to the acquisition, MYNAH had been a long-time Emerson alliance partner.

MYNAH produces solutions to allow plant engineers and technicians to test and improve process control strategies and train plant operators in offline, real-world scenarios before implementing them in live production. The addition of MYNAH will help support Emerson Automation Solutions and its Operational Certainty programme, designed to help industrial companies achieve top performance.

“Adding MYNAH’s simulation software and expertise allows us to provide customers with more advanced process simulation and training solutions. This will help improve plant performance, safety and profitability by allowing them to fully optimise their human and automation resources,” said Jamie Froedge, president, Process Systems and Solutions, Emerson Automation Solutions.

MYNAH’s Mimic Simulation Software is currently in use at more than 1,400 sites across 68 countries in industries ranging from hydrocarbon production to refining, chemical, pharmaceutical and biotechnology.

“We are excited to join Emerson in delivering greater operational value to the process industries,” said Martin Berutti, chief operating officer for MYNAH Technologies. “By leveraging Emerson’s vast global network we can help more organisations deal with generational shift changes in the workplace, while improving the performance of industrial plants.”

The terms of Emerson’s acquisition of MYNAH have not been disclosed.

MYNAH’s simulation models, including a bioreactor model for biotech organisations, help facilities to improve production and reduce risk.